Eli Lilly, Incyte get FDA EUA status for baricitinib plus remdesivir to treat Covid-19

This article was originally published here

The EUA status facilitates distribution and emergency use of baricitinib in combination with remdesivir in hospitalised adult and paediatric patients two years of age or older with suspected

The post Eli Lilly, Incyte get FDA EUA status for baricitinib plus remdesivir to treat Covid-19 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply